trending Market Intelligence /marketintelligence/en/news-insights/trending/6La1g_Z-cntD5J5eveR_Pg2 content esgSubNav
In This List

NeoGenomics prices $148.8M common stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


NeoGenomics prices $148.8M common stock offering

NeoGenomics Inc. priced an offering of 7 million common stock at $21.25 each.

The Fort Myers, Fla.-based company also granted underwriters a 30-day option to buy up to an additional 1,050,000 common shares at the same price.

The company, which focuses on cancer genetics testing, expects gross proceeds of $148.8 million from the offering. Net proceeds will be used for general corporate purposes.

NeoGenomics may also use the proceeds from the offer to acquire or invest in complementary business and technologies.

Morgan Stanley, SVB Leerink and William Blair acted as representatives of the underwriters and book-running managers for the offering, while Cantor, Craig-Hallum Capital Group, Needham & Co., Raymond James and Stephens Inc. acted as co-managers.